Activity And Safety Of Erlotinib As Second- And Third-line Treatment In Elderly Patients With Advanced Non-small Cell Lung Cancer: A Phase II Trial
David Rossi, Donatella Dennetta, Marcello Ugolini, Vincenzo Catalano, Paolo Alessandroni, Paolo Giordani, Anna Maria Baldelli, Virginia Casadei, Francesco Graziano, S. Luzi Fedeli
Twitter
Facebook
LinkedIn
Email